Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say
06:31pm, Tuesday, 30'th Jul 2024
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
06:11pm, Tuesday, 30'th Jul 2024
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.78 per share a year ago.
Pacira BioSciences Reports Second Quarter 2024 Financial Results
04:00pm, Tuesday, 30'th Jul 2024
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management
3 Biotech Stocks to Buy on the Dip: July 2024
06:00am, Monday, 29'th Jul 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian parad
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
10:57am, Wednesday, 17'th Jul 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
11:46am, Friday, 12'th Jul 2024
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
04:19pm, Wednesday, 10'th Jul 2024
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient envi
Top 5 Health Care Stocks That May Explode In July
08:40am, Monday, 08'th Jul 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
12:55pm, Wednesday, 03'rd Jul 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
12:35pm, Thursday, 06'th Jun 2024
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare C
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
04:05pm, Wednesday, 08'th May 2024
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate princip
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
12:36pm, Wednesday, 08'th May 2024
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
09:14pm, Tuesday, 07'th May 2024
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charle
